Analyst Models NeurAxis 12-Month Share Price Target At $14, 301% Higher Than Current Price ($NRXS)

Having just 1.21 million outstanding shares typically presents exceptionally well to a growth stock investor. But while it can fuel appreciable gains quickly, it can also cause downward pressure....

Related Keywords

Boston ,Massachusetts ,United States ,Brian Carrico ,Jack Enterprises ,Neuraxis Inc ,Boston Scientific Corp ,Goldman Small Cap Research ,Goldman Smallcap Research ,Hawk Point Media Group Llc ,Irritable Bowel Syndrome ,Functional Abdominal Pain ,Percutaneous Electrical Nerve Field Stimulation ,Price To Reach ,Smallcap Research ,Big Pharma ,Earning Considerable ,Chief Executive Officer ,Immediate Post Concussion Assessment ,Post Concussion Symptom Scale ,Balance Error Scoring Symptom ,Small Cap Research ,Point Media Group ,Eyed Jack Enterprises ,Private Securities Litigation Reform Act ,Hawk Point ,Markets ,